Noopept vs Semax
Both emerged from the Russian nootropic research programme, both target memory and attention via BDNF and NGF induction, and both are research chemicals in the UK. The chief practical difference is delivery: Noopept is orally active, Semax requires intranasal administration.
Side-by-side
| Noopept | Semax | |
|---|---|---|
| Chemistry | Proline dipeptide ester (peptidomimetic) | Heptapeptide (true peptide) |
| Route | Oral | Intranasal |
| Onset of effect | Hours (acute), days (cumulative) | Hours (acute), days (cumulative) |
| Active species | Cycloprolylglycine (metabolite) + parent | Semax peptide |
| Mechanism | Glutamate modulation + BDNF/NGF induction | BDNF/NGF induction + enkephalinase + monoamine |
| Clinical use (Russia) | Approved for cognitive indications | Approved for cerebrovascular indications |
| UK status | Research chemical | Research chemical |
The choice usually comes down to route
Researchers comparing Noopept and Semax in practice are rarely choosing between mechanisms — the BDNF/NGF induction is broadly similar. The deciding factor is almost always practical: Noopept is a small ester that survives the gut, so research protocols can use oral capsules. Semax is a true heptapeptide that does not, so protocols are intranasal. Pick the delivery your research design accommodates.